A therapeutic peptide that can prevent intestinal infections by increasing the expression of MUC3 by intestinal epithelial cells.

Summary
Serum Amyloid A (SAA) proteins are most commonly produced in
response to inflammatory infections and function by up-regulating
mucin production in the gut to prevent pathogenic bacterial
adhesion and subsequent colonization. Researchers at the
University of Nebraska have identified a novel SAA protein that is
detectable in the colostrums of several mammalian species.
Preliminary research suggests that a peptide fragment of this
protein can function as an antimicrobial agent, suitable for use as a
prophylactic treatment for gastrointestinal diseases such as
necrotizing enterocolitis and infectious diarrhea.

Market Value
Poor water quality is a major problem in many countries, leading to
many serious illnesses, such as traveler's diarrhea. This unique,
naturally occurring peptide has the potential to prophylactically
prevent intestinal infections from occurring. A further application for
the peptide includes its use in the management of feed stock to
prevent harmful pathogenic infections from decreasing livestock
production.

Features and Benefits
• Single Peptide
• Prophylactic in nature
• Peptide from naturally occurring protein
• Non-microbe Strain Specific

Early Stage

Issued patents and additional pending applications

(TID - 86)

UNeMed Corporation offers a variety of licensing options and collaborative development opportunities with the University of Nebraska Medical Center.